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Identification of Genes Important for Growth of Asymptomatic
Bacteriuria Escherichia coli in Urine
Rebecca M. Vejborg,a Mari R. de Evgrafov,a Minh Duy Phan,b Makrina Totsika,b Mark A. Schembri,b and Viktoria Hancocka
Epidemiology and Microbial Genomics, DTU Food, Technical University of Denmark, Kongens Lyngby, Denmark,a and Australian Infectious Diseases Research Centre,
School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, Australiab
Escherichia coli is the most important etiological agent of urinary tract infections (UTIs). Unlike uropathogenic E. coli, which
causes symptomatic infections, asymptomatic bacteriuria (ABU) E. coli strains typically lack essential virulence factors and colo-
nize the bladder in the absence of symptoms. While ABU E. coli can persist in the bladder for long periods of time, little is known
about the genetic determinants required for its growth and fitness in urine. To identify such genes, we have employed a trans-
poson mutagenesis approach using the prototypic ABU E. coli strain 83972 and the clinical ABU E. coli strain VR89. Six genes
involved in the biosynthesis of various amino acids and nucleobases were identified (carB, argE, argC, purA,metE, and ilvC), and
site-specific mutants were subsequently constructed in E. coli 83972 and E. coli VR89 for each of these genes. In all cases, these
mutants exhibited reduced growth rates and final cell densities in human urine. The growth defects could be complemented in
trans as well as by supplementation with the appropriate amino acid or nucleobase. When assessed in vivo in a mouse model, E.
coli 83972carAB and 83972argC showed a significantly reduced competitive advantage in the bladder and/or kidney during coin-
oculation experiments with the parent strain, whereas 83972metE and 83972ilvC did not. Taken together, our data have identi-
fied several biosynthesis pathways as new important fitness factors associated with the growth of ABU E. coli in human urine.
Urinary tract infections (UTIs) are among the most commonbacterial infections in humans, affecting millions of people
across the globe. It is estimated that there aremore than 10million
cases of UTIs in Western Europe alone every year. UTIs also ac-
count for 25 to 40% of all nosocomial infections, making these
infections an important medical and financial burden on our
health care systems (17). Urinary tract infections affect primarily
women; 40 to 50%of adultwomenwill experience at least oneUTI
episode during their lifetime (8, 33). A UTI usually starts as a
bladder infection but can, depending on the bacterial strain, as-
cend to the kidneys and may ultimately result in renal failure or
dissemination to the bloodstream. Themost important etiological
agent of UTIs is Escherichia coli, which is associated with more
than 80% of all such infections (34).
UTIs are classified into the following disease categories accord-
ing to the focal point and severity of the infection: bacteriuria (the
urine), cystitis (the bladder), pyelonephritis (the kidneys), and
urosepsis (the blood). E. coli strains that cause cystitis and pyelo-
nephritis have been studied extensively and are referred to as uro-
pathogenic E. coli (UPEC). A subset of UPEC strains also cause
urosepsis, and togetherwith strains that cause neonatalmeningitis
and respiratory infection, these strains are collectively referred to
as extraintestinal pathogenic E. coli (ExPEC) (18). In addition to
well-documented symptomatic infections,manyUTIs are asymp-
tomatic. E. coli is also themajor cause of asymptomatic bacteriuria
(ABU); E. coli ABU strains cause few or no symptoms in the in-
fected individual and establish bacteriuria in a commensal-like
state. Despite the high prevalence of ABU, the molecular mecha-
nisms associated with the ability of E. coli to establish this condi-
tion are not well understood. Previous studies have shown that
many ABU E. coli strains fail to express key virulence factors nor-
mally associated with pathogenic UPEC strains, suggesting that
this may constitute a mechanism of adaptation to long-term
asymptomatic colonization of the human bladder (27, 32, 41, 40).
E. coli 83972 represents the prototypic ABU strain; it was orig-
inally isolated from a young Swedish girl who carried it asymp-
tomatically for at least 3 years (4, 22). E. coli 83972 is well adapted
for growth in the human urinary tract, where it can establish long-
term bacteriuria (4, 15, 35). At the genome level, E. coli 83972
closely resembles thewell-characterized and highly virulentUPEC
isolate CFT073, suggesting that they may have a common ances-
tral origin (13, 19, 39). E. coli 83972 most likely represents a de-
generated uropathogen which has lost the ability to produce a
range of important virulence factors. It cannot adhere to bladder
epithelial cells due to a lack of functional fimbriae and it does not
activate host immune defenses during infection (20, 28). Never-
theless, E. coli 83972 grows well in human urine, with doubling
times in the order of 25 to 45min (12, 14, 27, 29). E. coli 83972 can
also outcompete virulent UPEC strains in human urine and in the
mouse bladder (29)—a phenotypic property that supports its use
in the prophylactic treatment of patients who are refractory to
conventional UTI therapy (5, 15). Extensive trials have suggested
that deliberate colonization of the bladder with E. coli 83972 can
prevent bacterial and fungal uropathogens from colonizing the
urinary tract (5, 36–38). One common feature of E. coli 83972 and
other ABU E. coli strains is the production of iron-chelating
siderophores (23, 41, 42). Indeed, E. coli 83972 produces entero-
bactin, salmochelin, aerobactin, and yersiniabactin (42), and the
genes responsible for the biosynthesis and transport of these mol-
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ecules are highly expressed during growth in the iron-limited con-
ditions of the human urinary tract (26).
Arguably, the ability to grow in human urine must be one of
the prerequisites for ABU E. coli strains to establish long-term
colonization of the human bladder. Bacterial metabolic processes
are clearly important in relation to the persistence of E. coli strains
in the urinary tract, withE. coli 83972 being an ideal strain for such
studies, allowing for delineation between fitness and virulence. In
this respect, we have previously shown, using transcriptomics,
that a number of genes are upregulated in E. coli 83972 during
growth in vivo in human urine compared to growth on laboratory
medium (26). Here we have utilized E. coli 83972 and an addi-
tional ABU clinical isolate (VR89) to identify novel genes required
for growth in human urine. Using a transposon mutagenesis ap-
proach, we show that genes involved in the biosynthesis of argi-
nine (argC, argE, and carAB), methionine (metE), valine and leu-
cine (ilvC), isoleucine (ilvA and ilvC), and adenine (purA) are
important factors associatedwith the growth andfitness of ABUE.
coli in human urine.
MATERIALS AND METHODS
Bacterial strains and growth medium. The strains used in this study are
listed in Table 1. All strains were grown at 37°C on solid or in liquid
modified Luria-Bertani (LB) medium or in pooled sterile filtered urine
collected from at least three healthy female volunteers with no history of
UTI or antibiotic use within the last 2months. The urinewas pooled, filter
sterilized, and stored at 4°C until use (within 1 to 2 days). Antibiotics were
added when required at the following concentrations: gentamicin, 5 g/
ml; kanamycin, 25 g/ml; chloramphenicol, 16 g/ml; ampicillin, 100
g/ml; and nalidixic acid, 50 g/ml. Amino acid and nucleobase supple-
ments were added at the following concentrations: uracil, 50 g/ml; argi-
nine, 100 g/ml; adenine, 50 g/ml; isoleucine, 100 g/ml; and valine,
100 g/ml.
Growth experiments. Monocultures were grown in pooled human
urine in 96-well microtiter plates inoculated to an optical density at
600 nm (OD600) of 0.01 under shaking conditions (300 rpm on an
orbital shaker) at 37°C. OD600 readings were acquired at 30-min in-
tervals until stationary phase was reached. Each experiment included
two to four replicates and was repeated at least three times. For com-
petition experiments, an ampicillin-resistant variant of E. coli 83972
(E. coli 83972AMP) was used instead of the wild-type E. coli 83972; E.
coli 83972AMP displayed a growth rate identical to that of wild-type E.
coli 83972 under all conditions tested. Mixed cultures were inoculated
into pooled human urine using a starting ratio of 1:1 and an initial
OD600 of 0.05. Samples from each culture were extracted at the start of
the cultivation, diluted, and cultured on LB plates with and without
ampicillin to confirm the starting ratios of CFU. The cultures were
then grown overnight at 37°C and 300 rpm on an orbital shaker. Sam-
ples were extracted after 16 h, diluted, and cultured on LB plates with
and without ampicillin. Each competition experiment was performed
in duplicate and repeated at least three times.
Transposon mutagenesis. Transposon mutant libraries were con-
structed using the mariner-based transposon system carried on plasmid
pBT20 (21). Bacterial suspensions of the donor (E. coli SM10-pir con-
taining pBT20) and the recipients (E. coli 83972NalR and E. coli
VR89NalR) were recovered from overnight plates and resuspended in LB
broth. These suspensions were adjusted to OD600s of 40 and 20, respec-
tively, andmixed in a 1:1 ratio. Aliquots of 50l were spotted on a dry LB
agar plate and incubated at 37°C for 6 h. The mating mixtures were sub-
sequently recovered from the plate, resuspended in LB, and cultured on
LB agar plates containing gentamicin and nalidixic acid. From these
plates, the individual colonies were inoculated into microtiter plates con-
taining LBbroth or sterile filtered humanurine. The plateswere incubated
statically overnight at 37°C and subsequently screened for mutants that
could grow in LB broth but not in human urine. The insertion sites were
determined using a semirandom PCR method (9).
Recombinant DNA techniques. Specific mutants of E. coli 83972 and
E. coli VR89 were constructed using the -red recombinase-based gene
inactivation system as previously described (6). The primers are listed in
Table 2. Following amplification, the PCR products were transformed
into E. coli 83972 and VR89 carrying the helper plasmid pKD46 and the
transformations were plated on selectivemedium. Deletionmutants were
verified by PCR (primers are listed in Table 2). The kanamycin resistance
cassette was subsequently removed by use of the flippase-encoding plas-
mid pCP20 (6). The plasmids pVR9-13 and pVR15-16 were constructed
by amplifying the relevant genes from CFT073 using the primers listed in
Table 2. PCR fragments were digested with BamHI and SalI or SphI and
cloned into pACYC184. The resulting seven plasmids were transformed
into the mutants to enable complementation.
Mouse model of UTI. Female C3H/HeJ mice (8 to 10 weeks) were
purchased from the Animal Resources Centre, Western Australia, and
housed in sterile cages with ad libitum access to sterile water. The mouse
model of UTI with competitive mixed infection was performed as previ-
ously described (1). Mice were inoculated with a mixture of 2.5  108
CFU of E. coli 83972AMP and 2.5 108 CFU of each E. coli 83972 mutant,
both grown for 20 h in LB medium. At 48 h after inoculation, urine was
collected from each mouse and then mice were euthanized and the blad-
ders and kidneys were excised. Bacterial numbers in the mouse urine,
TABLE 1 Strains and plasmids used in the study
E. coli strain or plasmid Relevant characteristicsa Reference
E. coli strains
83972 OR:K5:H, ABU isolate 4
83972Nal 83972, nalidixic acid resistant This study
83972Amp 83972, ampicillin resistant 7
VR89 ABU isolate 27
83972carAB This study
83972argE This study
83972argC This study
83972purA This study
83972metE This study
83972ilvA This study
83972ilvC This study
83972carAB::kan This study
83972argE::kan This study
83972argC::kan This study
83972purA::kan This study
83972metE::kan This study
83972ilvA::kan This study
83972ilvC::kan This study
VR89carAB::kan This study
VR89argE::kan This study
VR89argC::kan This study
VR89purA::kan This study
VR89metE::kan This study
VR89ilvC::kan This study
Plasmids
pACYC184 Cloning vector, Camr
pVR9 carAB cloned into pACYC184, Camr This study
pVR10 argE cloned into pACYC184, Camr This study
pVR11 argC cloned into pACYC184, Camr This study
pVR12 purA cloned into pACYC184, Camr This study
pVR13 metE cloned into pACYC184, Camr This study
pVR15 ilvA cloned into pACYC184, Camr This study
pVR16 ilvC cloned into pACYC184, Camr This study
a Camr, chloramphenicol resistance.
Vejborg et al.
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bladders, and kidneys were determined by plating on selective LB agar
plates and by colony counts. Themixed strainswere differentiated by their
antibiotic resistance with E. coli 83972AMP resistant to ampicillin and the
E. coli 83972 mutants resistant to kanamycin. Competitive fitness indices
were calculated by dividing the CFU/ml or CFU/0.1 g for each E. coli
83972 mutant by that of E. coli 83972AMP. Differences in colonization be-
tween E. coli 83972AMP and each of the mutants were tested using the Wil-
coxon matched-pairs signed-rank test. All experiments were carried out in
strict accordance with the recommendations in the Animal Care and Protec-
tion Act (25a) and the Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes (23a). Approval for mouse infection studies
was obtained from the University of Queensland Animal Ethics Committee
(SCMB/471/09/NHMRC [NF]).
Microarray analysis. The microarray results of the amino acid bio-
synthesis genes were extracted from a previously published transcrip-
tomic analysis of E. coli 83972 during growth in pooled human urine
and from urine specimens collected from three patients deliberately
colonized with E. coli 83972 (26). GeneChip E. coli Genome 2.0 arrays
(Affymetrix) were used for hybridization of the labeled cDNA. Three
chips were hybridized with samples grown in three individual flasks in
MOPS (morpholinepropanesulfonic acid) medium (including 0.2%
glucose and 0.02% Casamino acids), three chips were hybridized with
samples from cells grown in pooled human urine in three individual
flasks, and nine chips were hybridized with samples obtained in trip-
licate from three individual patients; no pooling of samples was per-
formed. The arrays were normalized, and fold changes during growth
in urine compared to planktonic growth in MOPS were calculated.
Microarray data accession number. The supporting microarray data
have been deposited in ArrayExpress (http://www.ebi.ac.uk/arrayexpress/)
with accession number E-MEXP-584.
TABLE 2 Primers used in the study
Primer purpose and name Sequence
Construction of deletion mutants
carAB forward GAGTGAATATTCTCTGGAGGGTGTTTTGATTAAGTCAGCGTAATGTGTAGGCTGGAGCTGCTTCG
carAB reverse CAGGGTGGTGTCGTAATGCACTTTATATTGCAGCGCACTGCCATATGAATATCCTCCTTA
argE forward GGGTGATCAGTTCGCGGGTGGGCTTGATAAACCTCGTCTCTAATGTGTAGGCTGGAGCTGCTTCG
argE reverse TACCGCCATTTATCGAGATTTACCGTGCTCTGATTGCCACATATGAATATCCTCCTTA
argC forward TTCAGCGCAAAGCAATGATGCGGGAAAGTTAATCTCCGATTAATGTGTAGGCTGGAGCTGCTTC
argC reverse GCACCGCTTGTGCCGCCGCGCCTTTCAGTAAGTTGTCTTCCATATGAATATCCTCCTTA
purA forward GACTGAACGGGCTAAATATGTTGTACGCTACCAGGGCGGTTAATGTGTAGGCTGGAGCTGCTTC
purA reverse ACGCGTCGAACGGGTCGCGCAGAATCATGGTTTCAGTACCATATGAATATCCTCCTTA
metE forward TATTGGGCGGGGAACTCCACGCGTGAAGAACTGCTGTAATGTGTAGGCTGGAGCTGCTTCG
metE reverse GGCCAGCCGCGCGTTTTCAGGCCACAGTCCGGGTTGACCCCATATGAATATCCTCCTTA
ilvA forward AAGAGCGGTACTACGTGCACCGGTTTACGAGGCGGCGCAGGTCTAATAGGCTGGAGCTGCTTCGAA
ilvA reverse GGTCGCCAAGTTCGAACGCCGCCAGTACGCGCCCGTAGTCCATATGAATATCCTCCTTA
ilvC forward CAGGGTAAAAAAGTAGTCATCGTCGGCTGTGGCGCACAGTAATGTGTAGGCTGGAGCTGCTTCG
ilvC reverse AGCCGCGCAGTTTCTTACCTACCTGCTCAATCGCATGGCATATGAATATCCTCCTTA
Verification of deletion mutants
dapA TGCGAGATGTGCTTGATCT
carB CATCGGCATTCAGCGCCAT
yijP GTTTAGCCTGGACTTCTGTG
argB ACGCCACCCAGTTTGATAA
yjeT TGAATTCGACAATCTGGCTG
yjeB TCACTCCACCAGCAATAATT
yigM GTCAACCTGATACTTCGCTA
metE TGCACCATGTTCGCCAGTG
ilvC TAACCCGCAACAGCAATACG
k1, pKD4 (reference) CAGTCATAGCCGAATAGCCT
k2, pKD4 (reference) CGGTGCCCTGAATGAACTGC
kt, pKD4 (reference) CGGCCACAGTCGATGAATCC
Complementation
carAB forward CGGCGGATCCGCTAACAGGAGGAATTAACCGTGAGTGAATATTCT
carAB reverse GCGCGTCGACTTATTTGATCTGCGC
argE forward CGGCGGATCCGCTAACAGGAGGAATTAACCATGAATATTGATACT
argE reverse GCGCGCATGCTTAATGCCAGCAAAA
argC forward CGGCGGATCCGCTAACAGGAGGAATTAACCATGTTGAATACGCTG
argC reverse GCGCGTCGACTTAAATAAGAGACTG
purA forward CGGCGGATCCGCTAACAGGAGGAATTAACCATGGGTAACAACGTC
purA reverse GGCGGTCGACTTACGCGTCGAACGG
metE forward CGGCGGATCCGCTAACAGGAGGAATTAACCATGACAATTCTTAAT
metE reverse GCCGGTCGACTCATCCCCGACGCAA
ilvA forward CGGCGGATCCGCTAACAGGAGGAATTAACCATGATGGCAGACTCA
ilvA reverse GCGCGTCGACTTAACCCGCCAAAAA
ilvC forward CGGCGGATCCGCTAACAGGAGGAATTAACCATGGCTAACTACTTC
ilvC reverse GCGCGTCGACTTAACCCGCAACAGC
Genes Required for Growth of ABU E. coli in Urine
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RESULTS
Identification of mutants deficient in urine growth. A trans-
posonmutagenesis approach was used to identify genes that are
important for the growth of two well-characterized ABU E. coli
strains in human urine, i.e., the prototypic E. coli 83972 and E.
coli VR89. A total of 960 and 1,152 transposon mutants of E.
coli strains 83972 and VR89, respectively, were screened based
on the following criteria: attenuated growth in sterile filtered
pooled human urine and normal growth in LB broth. In total,
11 mutants that displayed a 90% reduction in final cell den-
sity following overnight growth in pooled human urine were
identified. In order to identify the genes of interest, the location
of the transposon insertions was determined by semirandom
PCR. As illustrated in Fig. 1A, the insertions were located in
FIG 1 Growth mutants identified by transposon mutagenesis. (A) Identified insertion sites of the mariner transposon in the two E. coli strains 83972 (black
triangles) and VR89 (white triangles). The illustrated gene order and orientations refer to the genomic context of E. coliMG1655. (B) Biosynthesis pathways for
the amino acids arginine, methionine, leucine, valine, and isoleucine. The gene(s) encoding the enzyme responsible for each step is indicated. Genes that were
mutated (knocked out) in E. coli strain 83972 are indicated in boldface.
Vejborg et al.
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genes related to amino acid, purine, and pyrimidine biosynthe-
sis. Insertions were identified within carB, argE, argC, purA,
metE, and ilvC. The carAB operon encodes the carbamoyl-
phosphate synthetase, an essential enzyme in the biosynthesis
of arginine and an important component of the pyrimidine
metabolism (Fig. 1B). The metE gene product is required for
the terminal step of methionine biosynthesis (Fig. 1B). The ilvC
gene product is involved in one of the last common steps in the
isoleucine-valine biosynthesis pathways (Fig. 1B). The purA
gene encodes adenylosuccinate synthase, which catalyzes the
first committed step toward the de novo synthesis of adenine.
Notably, four of the six genes with insertions were identified in
several mutants independently and two of the six insertions,
i.e., argE and metE, were found in both strain backgrounds
(Fig. 1A). argC has previously been shown to be important for
the growth and virulence of a UPEC strain (31).
Characteristics ofmutants deficient inurine growth.To con-
firm the results obtained by the transposon mutagenesis screen,
deletion mutants were constructed for each individual gene by
-red-mediated homologous recombination. Six deletion mu-
tants were made in each strain background (83972 and VR89) to
validate the results. The resulting mutants were subsequently as-
sayed for growth in sterile filtered pooled human urine. All of the
mutants grew poorly in human urine (Fig. 2A). The sixmutants in
E. coli 83972 possessed a significantly reduced growth rate (7 to
25%of that observed for E. coli 83972) and achieved a significantly
reduced final cell density (8 to 34% of that observed for E. coli
83972) (Fig. 2B and 3). Similar results were obtained in E. coli
VR89 (data not shown).
IlvA catalyzes the first step in the isoleucine pathway and is not
important for biosynthesis of valine or leucine. Therefore, it was ex-
pected that an ilvA mutant would be less attenuated for growth in
urine than an ilvCmutant. In order to test this hypothesis, we con-
structed an ilvAmutant in E. coli 83972 and assessed its growth char-
acteristics togetherwith the ilvCmutant.As expected,when grown in
urine, the ilvAmutant grew better than the ilvCmutant but was still
significantly attenuated compared with the growth of the wild-
type strain (Fig. 2A). The final cell density achieved by the ilvA
FIG 2 Growth of E. coli 83972 and its isogenic mutants in human urine. (A) The curves are shown as means of four replicates, and error bars indicate standard
deviations (n1). (B) Growth rates of E. coli 83972 in human urine with and without addition of amino acids and/or nucleobases (black) and growth rates of its
mutants in urine without (white) and with (gray) addition of amino acids and/or nucleobases. Growth rates are displayed as means of triplicates of independent
experiments relative to the growth rate of E. coli 83972 grown in human urine with no addition of amino acids. Error bars indicate standard errors.
Genes Required for Growth of ABU E. coli in Urine
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mutant was significantly higher than those of the other mutants
and represented approximately 50% of that observed for the
wild-type strain (Fig. 3).
Mutants deficient in urine growth can be complemented in
trans. Each mutant generated was complemented with a plasmid
expressing its respective nonfunctional gene. The final cell density
following growth in pooled human urine was restored to wild-
type levels for the carAB, argC, purA,metE, ilvA, and ilvCmutants
(range of 86 to 121% of the final cell density of E. coli 83972) (Fig.
3). The argE mutant reached a final cell density that was 65% of
that of E. coli 83972.
Mutants deficient in urine growth can be rescued by supple-
mentation of amino acids. In order to assess whether the various
mutants could be rescued from their growth deficiency by end
product complementation, each mutant was grown in the pres-
ence of the amino acids or nucleobases for which it was auxotro-
phic. While the growth of E. coli 83972 was not significantly al-
tered by the presence of the supplements (growth rates and final
cell densities were 97 to 118%of those for growth in urine without
supplements), the growth of the mutants was fully restored by the
addition of amino acids and/or nucleobases. The growth rates of
the mutants were restored to 88 to 108% of that of the wild type
(Fig. 2B), while the final cell densities were 94 to 111% of that of
the wild type (Fig. 3). This demonstrates that these amino acids
and nucleobases are limiting in human urine and that the biosyn-
thesis pathways of arginine, methionine, valine, uracil, adenine,
and isoleucine are essential for efficient growth of E. coli 83972 in
human urine.
Global gene expression analysis of genes involved in amino
acid biosynthesis. We have previously examined the global gene
expression profile of E. coli 83972 during growth in urine—both
in vitro and in vivo (in human volunteers) (26). The expression
profile of E. coli 83972 obtained during growth in urine was com-
pared with that during exponential growth in minimal medium
(MOPS-glucose including 0.02% Casamino acids). The expres-
sion levels of the genes involved in the biosynthesis of amino acids
are displayed in Fig. 4. Of the six genes identified in our trans-
poson mutagenesis screen, four were significantly upregulated
during growth in urine compared to their levels during growth in
minimal medium, i.e., argC, argE,metE, and ilvCwere all induced
1.7- to 17-fold in vivo (Fig. 4). Indeed, themetE transcript was the
9th highest expressed in vivo of all 8,716 transcripts in the global
gene expression analysis of E. coli 83972. It should also be noted
that less than 5% of all 8,716 transcripts had absolute expression
levels above 1,000, revealing that many amino acid biosynthesis
geneswere highly expressed in general.Of the 10 highest expressed
amino acid-related genes in vivo, five were involved in biosynthe-
sis of leucine, valine, and isoleucine and four were involved in
biosynthesis of threonine, methionine, and lysine (Fig. 4). In con-
trast, genes involved in biosynthesis of phenylalanine, tyrosine,
and tryptophan were among the lowest expressed of all amino
acid-related genes in urine (9 of the 13 lowest among the 98 genes
displayed in Fig. 4).
Interestingly, the mutations that significantly reduced growth
in human urine (Fig. 1) were found among the amino acid path-
ways displaying the highest proportion of significantly upregu-
lated genes (Fig. 4). In theArg, LeuValIso, andThrMetLys
pathways, 73%, 73%, and 52%of the genes, respectively, displayed
significant upregulation in urine. Other pathways displaying a
high proportion of induced genes were the Glu and Ala pathways
(67% and 43%, respectively), while the remaining pathways
contained a significantly lower proportion of induced genes (0
to 25%). Although the numbers of genes represented in the Glu
and Ala pathways are comparably low, this may indicate that
the biosynthesis of glutamate and alanine might also be impor-
tant for growth in human urine. Taken together, the gene ex-
pression data support the growth profiles observed for our
amino acid mutants and suggest that these amino acids are
limiting in human urine.
Competition in pooled human urine.The severely attenuated
growth phenotype displayed by the mutants suggested that they
would be outcompeted by the parent E. coli 83972 strain during
mixed growth in pooled human urine. To investigate this, we pit-
ted an ampicillin-resistant version of E. coli 83972 (E. coli
FIG 3 Final cell density of E. coli 83972 and its isogenic mutants in human urine supplemented with the appropriate amino acids and/or nucleobases or
complemented with plasmid expressing the defunct gene. Black bars, wild-type E. coli 83972 with andwithout addition of amino acids and/or nucleobases; white
bars, isogenic mutants; light gray bars, isogenic mutants with addition of amino acids and/or nucleobases; dark gray bars, isogenic mutants complemented with
plasmids expressing genes corresponding to the defunct gene. Growth characteristics of the isogenic mutants and the corresponding mutant expressing the
control vector pACYC184 were identical. Values are means of at least triplicates, and error bars indicate standard errors.
Vejborg et al.
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83972AMP) against wild-type E. coli 83972 (control) and each mu-
tant using a 1:1 inoculation ratio. The number of CFU of each
strain was then enumerated after 16 h of growth. The growth of E.
coli strains 83972 and 83972AMP was identical, indicating the suit-
ability of E. coli 83972AMP for these assays. In the mixed competi-
tion assays, six of the seven mutants were significantly outcom-
peted by E. coli 83972AMP, which constituted 83 to 100% of the
final population after 16 h of growth (Student’s paired t test, P	
0.01) (Fig. 5). The exception was E. coli 83972ilvA, which was not
outcompeted by E. coli 83972AMP.
FIG 4 Expression levels of E. coli 83972 in minimal medium (MOPS) and human urine (in vitro and in vivo) of all genes involved in the biosynthesis of amino
acids, as determined bymicroarray analysis. Genes thatweremutated inE. coli 83972 are indicated in boldface. Asterisks indicate expression levels in humanurine
that were significantly higher than those in MOPS (P	 0.05).
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Contribution of genes required for growth in human urine
to colonization of the mouse urinary tract. To assess the role of
the genes identified in our transposon mutagenesis screen on col-
onization of the mouse urinary tract, we examined the ability of
the wild-type and mutant strains to survive in competitive-colo-
nization experiments. Mice were coinoculated with wild-type and
mutant strains (viz., 83972carAB, 83972argC, 83972metE, and
83972ilvC) in a 1:1 ratio. In the mouse model, E. coli 83972carAB
was significantly outcompeted by E. coli 83972 in the bladder (P

0.0156) and kidney (P
 0.0313) of infected mice (Fig. 6). Of the
remaining mutants, only the E. coli 83972argC strain exhibited a
colonization defect; this strain was significantly outcompeted by
E. coli 83972 in the kidney (P
 0.0313) of infectedmice. Interest-
ingly, no difference in total bacterial counts was observed between
E. coli 83972 and any of the mutants in the urine of infected mice
(Fig. 6A).
DISCUSSION
Our knowledge of the factors that are involved in the virulence of
UPEC has advanced significantly over the last few decades. We
currently have a relatively good understanding of the repertoire of
adhesins, invasins, and toxins that are necessary for uropathoge-
nicity (24). However, our knowledge of the physiological factors
required for growth and survival of E. coli in human urine, and in
the urinary tract, is limited. Relatively few reports have addressed
this important issue compared to the number of studies on viru-
lence. Nevertheless, the importance of metabolic processes in the
persistence and colonization of the urinary tract by bacterial
strains is increasingly appreciated (2, 3). Urine is a complex
growth medium. It contains significant amounts of urea and cre-
atinine but is iron limiting. Urine has also been reported to con-
tain essential amino acids, purines, and pyrimidines (25). How-
ever, it is unclear if these are available in concentrations that are
sufficient to support growth in the absence of de novo growth
factors for synthesis. Previous reports have suggested that the bio-
synthesis of arginine and guanine is important for growth and
virulence of uropathogens (31). In addition, a study by Hull and
Hull suggested a requirement for glutamine, serine, leucine, me-
thionine, phenylalanine, proline, and uracil (16).
Transcriptomic analyses of E. coli growing in human urine
from patients and in vitro have provided valuable information
about the nutritional requirement of UTI strains (11, 26, 29). In
order to understand how ABU strains grow and persist in the
urinary tract and to complement our transcriptomic data, we an-
alyzed transposon mutant libraries of E. coli ABU strains 83972
and VR89. Screening for mutants deficient in urine growth iden-
tified six genes required for efficient growth in human urine. The
mutants were defunct in genes involved in the biosynthesis of
arginine (carB, argC, and argE), methionine (metE), valine, iso-
leucine, and leucine (ilvC), as well as adenine and uracil (carB and
purA). Two genes, i.e., argE and metE, were identified indepen-
FIG5 Competition experiment in humanurine cultures betweenE. coli 83972
and its mutants, mixed 1:1 at the starting point. After 16 h of growth under
hydrodynamic conditions at 37°C, the number of CFU of each strain in the
mixed biofilm population was determined. The data shown are the means of
three independent experiments in different batches of urine, and error bars
indicate standard errors. wt, wild type.
FIG 6 Competitive colonization of mouse urine, bladder, and kidneys. E. coli
83972AMP and each mutant were mixed at a 1:1 ratio and inoculated into a
group of eightmice. Urine (A), bladders (B), and kidneys (C)were collected 48
h after inoculation and processed for quantitative colony counts. Asterisks
indicate significant differences in colonization.
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dently in both strain backgrounds. All six mutants, in both E. coli
strain 83972 and VR89, had severely affected growth rates (7 to
25% of that of the wild type) and reached a significantly reduced
final cell density (8 to 34% of that of the wild type) compared with
those of their isogenic parent strain. These six mutants were also
easily outcompeted by the wild-type strain during competition
experiments. Amino acid or nucleobase supplementation readily
rescued the growth deficiency of the mutants, demonstrating that
these growth factors are limiting in human urine.
To determine whether the metabolic genes identified through
transposon mutagenesis were required for the growth and fitness
of E. coliABU strains during colonization of the urinary tract, four
mutants were assayed in an ascending UTI mouse model, viz., E.
coli 83972carAB, 83972argC, 83972metE, and 83972ilvC. In these
experiments, there was no significant difference in the numbers of
mutant and wild-type cells recovered from the urine of infected
mice. These findings may result from differences in the composi-
tion of human and mouse urine. It is also possible that the con-
tinuous replenishment of nutrients in the urine of mice (unlike
the in vitro batch culture), as well as growth in the proximity of
epithelial cells and cellular debris, may contribute to these differ-
ences.
Some differences were observed with respect to bladder and
kidney colonization of the E. coli mutants 83972argC and
83972carAB. The mutant strain E. coli 83972argCwas impaired in
the colonization of the kidneys, while E. coli 83972carABwas out-
competed in both the bladder and the kidneys. This correlates well
with previous studies of an argC mutant of UPEC isolate CP9
whichwas also significantly impaired in colonization of themouse
kidneys but not in colonization of the bladder (31). We note that
our study involved the use of Toll-like receptor 4 (TLR4)-deficient
mice, a characteristic which likely accounts for the ability of E. coli
83972 to colonize the kidneys. Interestingly, a previous study
showed that argG does not significantly impact the growth and
persistence of UPEC strain CFT073 in the mouse UTI model (2).
This may suggest that different steps in the arginine biosynthesis
pathway have different effects on the fitness of UPEC strains in
vivo.
Several studies have demonstrated that iron is an important
limiting factor during growth in urine and that most E. coli strains
that colonize the urinary tract, including ABU isolates, have nu-
merous iron acquisition systems (10, 29). E. coli 83972 possesses
functional yersiniabactin-, enterobactin-, aerobactin-, salmoche-
lin-, and citrate-dependent iron transport systems (39, 42). Many
of the genes involved in these systems are highly upregulated dur-
ing growth in urine (14, 29). Asmany of these systems are function-
ally redundantwith respect to iron acquisition, itwas not unexpected
that our mutagenesis screen did not identify any iron acquisition
genes. Russo et al. found several urine-upregulated genes (i.e., iroN
and ure1) that were not essential for growth in urine (30). This dem-
onstrates the value of combining different experimental approaches,
namely, mutagenesis and transcriptomics.
Although our libraries were not saturated, our findings indi-
cate that the growth advantage displayed by E. coli 83972 com-
pared with the growth of pathogenic strains is not related to
unique biosynthetic pathways.Many of the same nutrients appear
to be required for both pathogenic (3, 16, 30, 31) and asymptom-
atic (present study) isolates. This is interesting in terms of delin-
eating between fitness per se and virulence. We note that the argC,
ilvA, ilvC, andmetE genes were also significantly upregulated (1.7-
to 15-fold) in the pyelonephritis isolate CFT073 grown in human
urine compared to their levels inminimalmedium (data extracted
from a previous microarray study [14]). This indicates that the
genes identified as important for growth of the two ABU E. coli
strains in the present study might also be important for growth
and colonization of UPEC isolates.
Based on genomic sequencing, E. coli 83972 differs surprisingly
little from highly pathogenic UTI strains, suggesting that genetic
adaptation to commensalism through gene loss and point muta-
tions—rather than distinct biosynthetic pathways—may explain
its superior growth characteristics (28, 39). Many virulence fac-
tors, fimbriae in particular, are costly to produce. It remains to be
determined if the loss of key virulence factors can increase fitness
for growth in urine; thismay very well be the case for E. coli 83972.
In conclusion, our results point to the classification of several
biosynthesis pathways as bona fide bacterial fitness factors. Such
findings may offer a novel target for the development of future
antimicrobial agents. Compounds that specifically inhibit one or
more metabolic pathways may have potential for the treatment of
symptomatic urinary tract infections.
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